Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 291

Similar articles for PubMed (Select 23583215)

1.

Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.

Roque DM, Bellone S, Buza N, Romani C, Cocco E, Bignotti E, Ravaggi A, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD.

Am J Obstet Gynecol. 2013 Jul;209(1):62.e1-9. doi: 10.1016/j.ajog.2013.04.017. Epub 2013 Apr 10.

PMID:
23583215
2.

Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.

Roque DM, Bellone S, English DP, Buza N, Cocco E, Gasparrini S, Bortolomai I, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Santin AD.

Cancer. 2013 Jul 15;119(14):2582-92. doi: 10.1002/cncr.28017. Epub 2013 Apr 12.

3.

Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel.

Roque DM, Buza N, Glasgow M, Bellone S, Bortolomai I, Gasparrini S, Cocco E, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Santin AD.

Clin Exp Metastasis. 2014 Jan;31(1):101-10. doi: 10.1007/s10585-013-9614-5. Epub 2013 Sep 5.

4.

Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro.

Paik D, Cocco E, Bellone S, Casagrande F, Bellone M, Siegel EE, Richter CE, Schwartz PE, Rutherford TJ, Santin AD.

Gynecol Oncol. 2010 Oct;119(1):140-5. doi: 10.1016/j.ygyno.2010.06.024. Epub 2010 Jul 31.

5.

Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression.

Carrara L, Guzzo F, Roque DM, Bellone S, Emiliano C, Sartori E, Pecorelli S, Schwartz PE, Rutherford TJ, Santin AD.

Gynecol Oncol. 2012 Apr;125(1):231-6. doi: 10.1016/j.ygyno.2011.12.446. Epub 2011 Dec 29.

6.

Molecular mechanisms of patupilone resistance.

Mozzetti S, Iantomasi R, De Maria I, Prislei S, Mariani M, Camperchioli A, Bartollino S, Gallo D, Scambia G, Ferlini C.

Cancer Res. 2008 Dec 15;68(24):10197-204. doi: 10.1158/0008-5472.CAN-08-2091.

7.

Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance.

Hetland TE, Hellesylt E, Flørenes VA, Tropé C, Davidson B, Kærn J.

Hum Pathol. 2011 Jul;42(7):1019-26. doi: 10.1016/j.humpath.2010.10.025. Epub 2011 Feb 11.

PMID:
21315408
8.

Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin.

Umezu T, Shibata K, Kajiyama H, Terauchi M, Ino K, Nawa A, Kikkawa F.

Int J Gynecol Pathol. 2008 Apr;27(2):207-12. doi: 10.1097/PGP.0b013e318156c838.

PMID:
18317222
9.

Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma.

Aoki D, Oda Y, Hattori S, Taguchi K, Ohishi Y, Basaki Y, Oie S, Suzuki N, Kono S, Tsuneyoshi M, Ono M, Yanagawa T, Kuwano M.

Clin Cancer Res. 2009 Feb 15;15(4):1473-80. doi: 10.1158/1078-0432.CCR-08-1274.

10.

Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.

O'Reilly T, Wartmann M, Brueggen J, Allegrini PR, Floersheimer A, Maira M, McSheehy PM.

Cancer Chemother Pharmacol. 2008 Nov;62(6):1045-54. doi: 10.1007/s00280-008-0695-9. Epub 2008 Feb 27.

PMID:
18301895
11.

A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.

Cai P, Lu P, Sharom FJ, Fang WS.

Cancer Lett. 2013 Dec 1;341(2):214-23. doi: 10.1016/j.canlet.2013.08.010. Epub 2013 Aug 11.

PMID:
23941826
12.

Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary.

Choi CH, Sung CO, Kim HJ, Lee YY, Song SY, Song T, Kim J, Kim TJ, Lee JW, Bae DS, Kim BG.

Hum Pathol. 2013 Jun;44(6):1017-23. doi: 10.1016/j.humpath.2012.08.024. Epub 2013 Jan 3.

PMID:
23290009
13.

Class III b-tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents?

English DP, Roque DM, Santin AD.

Expert Rev Anticancer Ther. 2013 Jan;13(1):63-74. doi: 10.1586/era.12.158. Review.

PMID:
23259428
14.

Low expression of the X-linked ribosomal protein S4 in human serous epithelial ovarian cancer is associated with a poor prognosis.

Tsofack SP, Meunier L, Sanchez L, Madore J, Provencher D, Mes-Masson AM, Lebel M.

BMC Cancer. 2013 Jun 22;13:303. doi: 10.1186/1471-2407-13-303.

15.

Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.

Furlong F, Fitzpatrick P, O'Toole S, Phelan S, McGrogan B, Maguire A, O'Grady A, Gallagher M, Prencipe M, McGoldrick A, McGettigan P, Brennan D, Sheils O, Martin C, W Kay E, O'Leary J, McCann A.

J Pathol. 2012 Apr;226(5):746-55. doi: 10.1002/path.3035. Epub 2012 Jan 17. Erratum in: J Pathol. 2014 Feb;232(3):e1.

16.

Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.

Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Int J Gynecol Cancer. 2009 Jul;19(5):860-6. doi: 10.1111/IGC.0b013e3181a8331f.

PMID:
19574774
17.

Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.

Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli E, Ranelletti FO, Ferrandina G, Scambia G.

Clin Cancer Res. 2005 Jan 1;11(1):298-305.

18.
19.

Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study.

Mok TS, Choi E, Yau D, Johri A, Yeo W, Chan AT, Wong C.

Oncology. 2006;71(3-4):292-6. Epub 2007 Jul 26.

PMID:
17657173
20.

Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo.

Hofstetter B, Vuong V, Broggini-Tenzer A, Bodis S, Ciernik IF, Fabbro D, Wartmann M, Folkers G, Pruschy M.

Clin Cancer Res. 2005 Feb 15;11(4):1588-96.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk